Look up one drug

Reason for Use code 186 For acute treatment of deep venous thrombosis (DVT), for a maximum of three weeks; Coverage limit: LU Authorization Period: 1 year Reason for Use code 187 For DVT in pregnant or lactating females; Coverage limit: LU Authorization Period: 1 year Reason for Use code 188 For DVT in patients whom treatment with warfarin is not tolerated, or contraindicated; Coverage limit: LU Authorization Period: 1 year Reason for Use code 189 For DVT in patients who have failed treatment with warfarin. Coverage limit: LU Authorization Period: 1 year Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Dalteparin Brand(s): Fragmin DOSAGE FORM/ STRENGTH: Check formulary or e-formulary for funded products For peri-operative bridging for patients who require long-term warfarin therapy and must temporarily discontinue it before and after surgery, and who are at moderate- to high-risk for an embolic event while off warfarin. Standard Approval Duration: As requested up to a maximum of 10 days before the date of surgery plus up to 7 days after surgery. For post-operative prophylaxis of DVT for patients who had hip or knee surgery, and cannot use warfarin. Standard Approval Duration: As requested up to a maximum of 30 days starting on the day of surgery. For the post-operative prophylaxis of venous thromboembolism following abdominal or pelvic surgery for cancer in patients who do not have a history of or risk factors for heparin-induced thrombocytopenia. Standard Approval Duration: Maximum of 30 days For extended treatment of symptomatic acute venous thromboembolism (VTE) in patients with cancer for whom warfarin treatment is not appropriate on a case-by-case basis. Standard Approval Duration: 6 months 28 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 28, record 7, corpus 2025-01-01; name match only, not an eligibility decision Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Dalteparin Brand(s): Fragmin DOSAGE FORM/ STRENGTH: Check e-formulary for funded strengths 1. For peri-operative bridging for patients who require long-term warfarin therapy and must temporarily discontinue it before and after surgery, and who are at moderate- to high-risk for an embolic event while off warfarin. Standard Approval Duration: As requested up to a maximum of 10 days before the date of surgery plus up to 7 days after the date of hospital discharge 2. For post-operative prophylaxis of DVT for patients who had hip or knee surgery and cannot use warfarin. Standard Approval Duration: As requested up to a maximum of 30 days starting on the day of surgery 3. For the post-operative prophylaxis of venous thromboembolism following abdominal or pelvic surgery for cancer in patients who do not have a history of or risk factors for heparin-induced thrombocytopenia. Standard Approval Duration: Maximum of 30 days. 4. For extended treatment of symptomatic acute venous thromboembolism (VTE) in patients with cancer, who cannot use warfarin. Standard Approval Duration: As requested up to 6 months 469 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 469, record 308, corpus 2025-01-01; name match only, not an eligibility decision

Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 15, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days | (ontario.ca, Updated September 15, 2026 ↗) For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated September 15, 2026 ↗)

Fragmin · DIN 02132621 Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01 Health Canada: Marketed since 2005-07-12 · brand FRAGMIN · ATC B01AB04 DALTEPARIN · form Solution · route Intravenous, Subcutaneous · ingredients DALTEPARIN SODIUM 2500 UNIT/0.2ML · company Pfizer canada ulc · schedule Prescription

DIN 02132621: Fragmin Raw flags: sec12=Y, sec3=Y Item: 201200038; group id 253; item number 0450; lccId 00045; manufacturer id PFI Source form: Inj Pref Syr; strength: 2500IU/0.2mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $6.0498; ministry $6.0498 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02132621 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18307

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02132621

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Reason for Use code 186 For acute treatment of deep venous thrombosis (DVT), for a maximum of three weeks; Coverage limit: LU Authorization Period: 1 year Reason for Use code 187 For DVT in pregnant or lactating females; Coverage limit: LU Authorization Period: 1 year Reason for Use code 188 For DVT in patients whom treatment with warfarin is not tolerated, or contraindicated; Coverage limit: LU Authorization Period: 1 year Reason for Use code 189 For DVT in patients who have failed treatment with warfarin. Coverage limit: LU Authorization Period: 1 year Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Dalteparin Brand(s): Fragmin DOSAGE FORM/ STRENGTH: Check formulary or e-formulary for funded products For peri-operative bridging for patients who require long-term warfarin therapy and must temporarily discontinue it before and after surgery, and who are at moderate- to high-risk for an embolic event while off warfarin. Standard Approval Duration: As requested up to a maximum of 10 days before the date of surgery plus up to 7 days after surgery. For post-operative prophylaxis of DVT for patients who had hip or knee surgery, and cannot use warfarin. Standard Approval Duration: As requested up to a maximum of 30 days starting on the day of surgery. For the post-operative prophylaxis of venous thromboembolism following abdominal or pelvic surgery for cancer in patients who do not have a history of or risk factors for heparin-induced thrombocytopenia. Standard Approval Duration: Maximum of 30 days For extended treatment of symptomatic acute venous thromboembolism (VTE) in patients with cancer for whom warfarin treatment is not appropriate on a case-by-case basis. Standard Approval Duration: 6 months 28 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 28, record 7, corpus 2025-01-01; name match only, not an eligibility decision Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Dalteparin Brand(s): Fragmin DOSAGE FORM/ STRENGTH: Check e-formulary for funded strengths 1. For peri-operative bridging for patients who require long-term warfarin therapy and must temporarily discontinue it before and after surgery, and who are at moderate- to high-risk for an embolic event while off warfarin. Standard Approval Duration: As requested up to a maximum of 10 days before the date of surgery plus up to 7 days after the date of hospital discharge 2. For post-operative prophylaxis of DVT for patients who had hip or knee surgery and cannot use warfarin. Standard Approval Duration: As requested up to a maximum of 30 days starting on the day of surgery 3. For the post-operative prophylaxis of venous thromboembolism following abdominal or pelvic surgery for cancer in patients who do not have a history of or risk factors for heparin-induced thrombocytopenia. Standard Approval Duration: Maximum of 30 days. 4. For extended treatment of symptomatic acute venous thromboembolism (VTE) in patients with cancer, who cannot use warfarin. Standard Approval Duration: As requested up to 6 months 469 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 469, record 308, corpus 2025-01-01; name match only, not an eligibility decision

Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 15, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days | (ontario.ca, Updated September 15, 2026 ↗) For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated September 15, 2026 ↗)

Fragmin · DIN 02430789 Manufacturer: Pfizer Canada Inc.; listing date 2016-03-30 Health Canada: Marketed since 2015-03-25 · brand FRAGMIN · ATC B01AB04 DALTEPARIN · form Solution · route Subcutaneous, Intravenous · ingredients DALTEPARIN SODIUM 3500 UNIT/0.28ML · company Pfizer canada ulc · schedule Prescription

DIN 02430789: Fragmin Raw flags: sec12=Y, sec3=Y Item: 201200099; group id 253; item number 0448; lccId 00045; manufacturer id PFI Source form: Inj Pref Syr; strength: 3500IU/0.28mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $8.4689; ministry $8.4689 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02430789 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91522

Shortage status: resolved shortage (ended 2019-05-07); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02430789

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Reason for Use code 186 For acute treatment of deep venous thrombosis (DVT), for a maximum of three weeks; Coverage limit: LU Authorization Period: 1 year Reason for Use code 187 For DVT in pregnant or lactating females; Coverage limit: LU Authorization Period: 1 year Reason for Use code 188 For DVT in patients whom treatment with warfarin is not tolerated, or contraindicated; Coverage limit: LU Authorization Period: 1 year Reason for Use code 189 For DVT in patients who have failed treatment with warfarin. Coverage limit: LU Authorization Period: 1 year Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Dalteparin Brand(s): Fragmin DOSAGE FORM/ STRENGTH: Check formulary or e-formulary for funded products For peri-operative bridging for patients who require long-term warfarin therapy and must temporarily discontinue it before and after surgery, and who are at moderate- to high-risk for an embolic event while off warfarin. Standard Approval Duration: As requested up to a maximum of 10 days before the date of surgery plus up to 7 days after surgery. For post-operative prophylaxis of DVT for patients who had hip or knee surgery, and cannot use warfarin. Standard Approval Duration: As requested up to a maximum of 30 days starting on the day of surgery. For the post-operative prophylaxis of venous thromboembolism following abdominal or pelvic surgery for cancer in patients who do not have a history of or risk factors for heparin-induced thrombocytopenia. Standard Approval Duration: Maximum of 30 days For extended treatment of symptomatic acute venous thromboembolism (VTE) in patients with cancer for whom warfarin treatment is not appropriate on a case-by-case basis. Standard Approval Duration: 6 months 28 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 28, record 7, corpus 2025-01-01; name match only, not an eligibility decision Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Dalteparin Brand(s): Fragmin DOSAGE FORM/ STRENGTH: Check e-formulary for funded strengths 1. For peri-operative bridging for patients who require long-term warfarin therapy and must temporarily discontinue it before and after surgery, and who are at moderate- to high-risk for an embolic event while off warfarin. Standard Approval Duration: As requested up to a maximum of 10 days before the date of surgery plus up to 7 days after the date of hospital discharge 2. For post-operative prophylaxis of DVT for patients who had hip or knee surgery and cannot use warfarin. Standard Approval Duration: As requested up to a maximum of 30 days starting on the day of surgery 3. For the post-operative prophylaxis of venous thromboembolism following abdominal or pelvic surgery for cancer in patients who do not have a history of or risk factors for heparin-induced thrombocytopenia. Standard Approval Duration: Maximum of 30 days. 4. For extended treatment of symptomatic acute venous thromboembolism (VTE) in patients with cancer, who cannot use warfarin. Standard Approval Duration: As requested up to 6 months 469 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 469, record 308, corpus 2025-01-01; name match only, not an eligibility decision

Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 15, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days | (ontario.ca, Updated September 15, 2026 ↗) For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated September 15, 2026 ↗)

Fragmin · DIN 02132648 Manufacturer: Pfizer Canada Inc.; listing date 1997-04-10 Health Canada: Marketed since 2005-05-03 · brand FRAGMIN · ATC B01AB04 DALTEPARIN · form Solution · route Subcutaneous, Intravenous · ingredients DALTEPARIN SODIUM 5000 UNIT/0.2ML · company Pfizer canada ulc · schedule Prescription

DIN 02132648: Fragmin Raw flags: sec12=Y, sec3=Y Item: 201200040; group id 253; item number 0451; lccId 00045; manufacturer id PFI Source form: Inj Pref Syr; strength: 5000IU/0.2mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $12.0996; ministry $12.0996 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02132648 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18306

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02132648

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Reason for Use code 186 For acute treatment of deep venous thrombosis (DVT), for a maximum of three weeks; Coverage limit: LU Authorization Period: 1 year Reason for Use code 187 For DVT in pregnant or lactating females; Coverage limit: LU Authorization Period: 1 year Reason for Use code 188 For DVT in patients whom treatment with warfarin is not tolerated, or contraindicated; Coverage limit: LU Authorization Period: 1 year Reason for Use code 189 For DVT in patients who have failed treatment with warfarin. Coverage limit: LU Authorization Period: 1 year Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Dalteparin Brand(s): Fragmin DOSAGE FORM/ STRENGTH: Check formulary or e-formulary for funded products For peri-operative bridging for patients who require long-term warfarin therapy and must temporarily discontinue it before and after surgery, and who are at moderate- to high-risk for an embolic event while off warfarin. Standard Approval Duration: As requested up to a maximum of 10 days before the date of surgery plus up to 7 days after surgery. For post-operative prophylaxis of DVT for patients who had hip or knee surgery, and cannot use warfarin. Standard Approval Duration: As requested up to a maximum of 30 days starting on the day of surgery. For the post-operative prophylaxis of venous thromboembolism following abdominal or pelvic surgery for cancer in patients who do not have a history of or risk factors for heparin-induced thrombocytopenia. Standard Approval Duration: Maximum of 30 days For extended treatment of symptomatic acute venous thromboembolism (VTE) in patients with cancer for whom warfarin treatment is not appropriate on a case-by-case basis. Standard Approval Duration: 6 months 28 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 28, record 7, corpus 2025-01-01; name match only, not an eligibility decision Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Dalteparin Brand(s): Fragmin DOSAGE FORM/ STRENGTH: Check e-formulary for funded strengths 1. For peri-operative bridging for patients who require long-term warfarin therapy and must temporarily discontinue it before and after surgery, and who are at moderate- to high-risk for an embolic event while off warfarin. Standard Approval Duration: As requested up to a maximum of 10 days before the date of surgery plus up to 7 days after the date of hospital discharge 2. For post-operative prophylaxis of DVT for patients who had hip or knee surgery and cannot use warfarin. Standard Approval Duration: As requested up to a maximum of 30 days starting on the day of surgery 3. For the post-operative prophylaxis of venous thromboembolism following abdominal or pelvic surgery for cancer in patients who do not have a history of or risk factors for heparin-induced thrombocytopenia. Standard Approval Duration: Maximum of 30 days. 4. For extended treatment of symptomatic acute venous thromboembolism (VTE) in patients with cancer, who cannot use warfarin. Standard Approval Duration: As requested up to 6 months 469 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 469, record 308, corpus 2025-01-01; name match only, not an eligibility decision

Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 15, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days | (ontario.ca, Updated September 15, 2026 ↗) For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated September 15, 2026 ↗)

Fragmin · DIN 02352648 Manufacturer: Pfizer Canada Inc.; listing date 2012-02-29 Health Canada: Marketed since 2011-02-01 · brand FRAGMIN · ATC B01AB04 DALTEPARIN · form Solution · route Subcutaneous, Intravenous · ingredients DALTEPARIN SODIUM 7500 UNIT/0.3ML · company Pfizer canada ulc · schedule Prescription

DIN 02352648: Fragmin Raw flags: sec12=Y, sec3=Y Item: 201200083; group id 253; item number 0449; lccId 00045; manufacturer id PFI Source form: Inj Pref Syr; strength: 7500IU/0.3mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $18.1504; ministry $18.1504 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02352648 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83790

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02352648

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Reason for Use code 186 For acute treatment of deep venous thrombosis (DVT), for a maximum of three weeks; Coverage limit: LU Authorization Period: 1 year Reason for Use code 187 For DVT in pregnant or lactating females; Coverage limit: LU Authorization Period: 1 year Reason for Use code 188 For DVT in patients whom treatment with warfarin is not tolerated, or contraindicated; Coverage limit: LU Authorization Period: 1 year Reason for Use code 189 For DVT in patients who have failed treatment with warfarin. Coverage limit: LU Authorization Period: 1 year Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Dalteparin Brand(s): Fragmin DOSAGE FORM/ STRENGTH: Check formulary or e-formulary for funded products For peri-operative bridging for patients who require long-term warfarin therapy and must temporarily discontinue it before and after surgery, and who are at moderate- to high-risk for an embolic event while off warfarin. Standard Approval Duration: As requested up to a maximum of 10 days before the date of surgery plus up to 7 days after surgery. For post-operative prophylaxis of DVT for patients who had hip or knee surgery, and cannot use warfarin. Standard Approval Duration: As requested up to a maximum of 30 days starting on the day of surgery. For the post-operative prophylaxis of venous thromboembolism following abdominal or pelvic surgery for cancer in patients who do not have a history of or risk factors for heparin-induced thrombocytopenia. Standard Approval Duration: Maximum of 30 days For extended treatment of symptomatic acute venous thromboembolism (VTE) in patients with cancer for whom warfarin treatment is not appropriate on a case-by-case basis. Standard Approval Duration: 6 months 28 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 28, record 7, corpus 2025-01-01; name match only, not an eligibility decision Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Dalteparin Brand(s): Fragmin DOSAGE FORM/ STRENGTH: Check e-formulary for funded strengths 1. For peri-operative bridging for patients who require long-term warfarin therapy and must temporarily discontinue it before and after surgery, and who are at moderate- to high-risk for an embolic event while off warfarin. Standard Approval Duration: As requested up to a maximum of 10 days before the date of surgery plus up to 7 days after the date of hospital discharge 2. For post-operative prophylaxis of DVT for patients who had hip or knee surgery and cannot use warfarin. Standard Approval Duration: As requested up to a maximum of 30 days starting on the day of surgery 3. For the post-operative prophylaxis of venous thromboembolism following abdominal or pelvic surgery for cancer in patients who do not have a history of or risk factors for heparin-induced thrombocytopenia. Standard Approval Duration: Maximum of 30 days. 4. For extended treatment of symptomatic acute venous thromboembolism (VTE) in patients with cancer, who cannot use warfarin. Standard Approval Duration: As requested up to 6 months 469 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 469, record 308, corpus 2025-01-01; name match only, not an eligibility decision

Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 15, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days | (ontario.ca, Updated September 15, 2026 ↗) For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated September 15, 2026 ↗)

Fragmin · DIN 02352656 Manufacturer: Pfizer Canada Inc.; listing date 2011-03-15 Health Canada: Marketed since 2011-02-01 · brand FRAGMIN · ATC B01AB04 DALTEPARIN · form Solution · route Intravenous, Subcutaneous · ingredients DALTEPARIN SODIUM 10000 UNIT/0.4ML · company Pfizer canada ulc · schedule Prescription

DIN 02352656: Fragmin Raw flags: sec12=Y, sec3=Y Item: 201200064; group id 253; item number 0452; lccId 00045; manufacturer id PFI Source form: Inj Pref Syr; strength: 10000IU/0.4mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $24.2012; ministry $24.2012 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02352656 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83791

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02352656

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Reason for Use code 186 For acute treatment of deep venous thrombosis (DVT), for a maximum of three weeks; Coverage limit: LU Authorization Period: 1 year Reason for Use code 187 For DVT in pregnant or lactating females; Coverage limit: LU Authorization Period: 1 year Reason for Use code 188 For DVT in patients whom treatment with warfarin is not tolerated, or contraindicated; Coverage limit: LU Authorization Period: 1 year Reason for Use code 189 For DVT in patients who have failed treatment with warfarin. Coverage limit: LU Authorization Period: 1 year Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Dalteparin Brand(s): Fragmin DOSAGE FORM/ STRENGTH: Check formulary or e-formulary for funded products For peri-operative bridging for patients who require long-term warfarin therapy and must temporarily discontinue it before and after surgery, and who are at moderate- to high-risk for an embolic event while off warfarin. Standard Approval Duration: As requested up to a maximum of 10 days before the date of surgery plus up to 7 days after surgery. For post-operative prophylaxis of DVT for patients who had hip or knee surgery, and cannot use warfarin. Standard Approval Duration: As requested up to a maximum of 30 days starting on the day of surgery. For the post-operative prophylaxis of venous thromboembolism following abdominal or pelvic surgery for cancer in patients who do not have a history of or risk factors for heparin-induced thrombocytopenia. Standard Approval Duration: Maximum of 30 days For extended treatment of symptomatic acute venous thromboembolism (VTE) in patients with cancer for whom warfarin treatment is not appropriate on a case-by-case basis. Standard Approval Duration: 6 months 28 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 28, record 7, corpus 2025-01-01; name match only, not an eligibility decision Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Dalteparin Brand(s): Fragmin DOSAGE FORM/ STRENGTH: Check e-formulary for funded strengths 1. For peri-operative bridging for patients who require long-term warfarin therapy and must temporarily discontinue it before and after surgery, and who are at moderate- to high-risk for an embolic event while off warfarin. Standard Approval Duration: As requested up to a maximum of 10 days before the date of surgery plus up to 7 days after the date of hospital discharge 2. For post-operative prophylaxis of DVT for patients who had hip or knee surgery and cannot use warfarin. Standard Approval Duration: As requested up to a maximum of 30 days starting on the day of surgery 3. For the post-operative prophylaxis of venous thromboembolism following abdominal or pelvic surgery for cancer in patients who do not have a history of or risk factors for heparin-induced thrombocytopenia. Standard Approval Duration: Maximum of 30 days. 4. For extended treatment of symptomatic acute venous thromboembolism (VTE) in patients with cancer, who cannot use warfarin. Standard Approval Duration: As requested up to 6 months 469 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 469, record 308, corpus 2025-01-01; name match only, not an eligibility decision

Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 15, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days | (ontario.ca, Updated September 15, 2026 ↗) For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated September 15, 2026 ↗)

Fragmin · DIN 02352664 Manufacturer: Pfizer Canada Inc.; listing date 2011-03-15 Health Canada: Marketed since 2011-02-01 · brand FRAGMIN · ATC B01AB04 DALTEPARIN · form Solution · route Intravenous, Subcutaneous · ingredients DALTEPARIN SODIUM 12500 UNIT/0.5ML · company Pfizer canada ulc · schedule Prescription

DIN 02352664: Fragmin Raw flags: sec12=Y, sec3=Y Item: 201200065; group id 253; item number 0453; lccId 00045; manufacturer id PFI Source form: Inj Pref Syr; strength: 12500IU/0.5mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $30.2520; ministry $30.2520 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02352664 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83792

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02352664

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Reason for Use code 186 For acute treatment of deep venous thrombosis (DVT), for a maximum of three weeks; Coverage limit: LU Authorization Period: 1 year Reason for Use code 187 For DVT in pregnant or lactating females; Coverage limit: LU Authorization Period: 1 year Reason for Use code 188 For DVT in patients whom treatment with warfarin is not tolerated, or contraindicated; Coverage limit: LU Authorization Period: 1 year Reason for Use code 189 For DVT in patients who have failed treatment with warfarin. Coverage limit: LU Authorization Period: 1 year Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Dalteparin Brand(s): Fragmin DOSAGE FORM/ STRENGTH: Check formulary or e-formulary for funded products For peri-operative bridging for patients who require long-term warfarin therapy and must temporarily discontinue it before and after surgery, and who are at moderate- to high-risk for an embolic event while off warfarin. Standard Approval Duration: As requested up to a maximum of 10 days before the date of surgery plus up to 7 days after surgery. For post-operative prophylaxis of DVT for patients who had hip or knee surgery, and cannot use warfarin. Standard Approval Duration: As requested up to a maximum of 30 days starting on the day of surgery. For the post-operative prophylaxis of venous thromboembolism following abdominal or pelvic surgery for cancer in patients who do not have a history of or risk factors for heparin-induced thrombocytopenia. Standard Approval Duration: Maximum of 30 days For extended treatment of symptomatic acute venous thromboembolism (VTE) in patients with cancer for whom warfarin treatment is not appropriate on a case-by-case basis. Standard Approval Duration: 6 months 28 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 28, record 7, corpus 2025-01-01; name match only, not an eligibility decision Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Dalteparin Brand(s): Fragmin DOSAGE FORM/ STRENGTH: Check e-formulary for funded strengths 1. For peri-operative bridging for patients who require long-term warfarin therapy and must temporarily discontinue it before and after surgery, and who are at moderate- to high-risk for an embolic event while off warfarin. Standard Approval Duration: As requested up to a maximum of 10 days before the date of surgery plus up to 7 days after the date of hospital discharge 2. For post-operative prophylaxis of DVT for patients who had hip or knee surgery and cannot use warfarin. Standard Approval Duration: As requested up to a maximum of 30 days starting on the day of surgery 3. For the post-operative prophylaxis of venous thromboembolism following abdominal or pelvic surgery for cancer in patients who do not have a history of or risk factors for heparin-induced thrombocytopenia. Standard Approval Duration: Maximum of 30 days. 4. For extended treatment of symptomatic acute venous thromboembolism (VTE) in patients with cancer, who cannot use warfarin. Standard Approval Duration: As requested up to 6 months 469 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 469, record 308, corpus 2025-01-01; name match only, not an eligibility decision

Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 15, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days | (ontario.ca, Updated September 15, 2026 ↗) For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated September 15, 2026 ↗)

Fragmin · DIN 02352672 Manufacturer: Pfizer Canada Inc.; listing date 2011-03-15 Health Canada: Marketed since 2011-02-01 · brand FRAGMIN · ATC B01AB04 DALTEPARIN · form Solution · route Intravenous, Subcutaneous · ingredients DALTEPARIN SODIUM 15000 UNIT/0.6ML · company Pfizer canada ulc · schedule Prescription

DIN 02352672: Fragmin Raw flags: sec12=Y, sec3=Y Item: 201200066; group id 253; item number 0454; lccId 00045; manufacturer id PFI Source form: Inj Pref Syr; strength: 15000IU/0.6mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $36.2927; ministry $36.2927 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02352672 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83793

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02352672

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Reason for Use code 186 For acute treatment of deep venous thrombosis (DVT), for a maximum of three weeks; Coverage limit: LU Authorization Period: 1 year Reason for Use code 187 For DVT in pregnant or lactating females; Coverage limit: LU Authorization Period: 1 year Reason for Use code 188 For DVT in patients whom treatment with warfarin is not tolerated, or contraindicated; Coverage limit: LU Authorization Period: 1 year Reason for Use code 189 For DVT in patients who have failed treatment with warfarin. Coverage limit: LU Authorization Period: 1 year Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Dalteparin Brand(s): Fragmin DOSAGE FORM/ STRENGTH: Check formulary or e-formulary for funded products For peri-operative bridging for patients who require long-term warfarin therapy and must temporarily discontinue it before and after surgery, and who are at moderate- to high-risk for an embolic event while off warfarin. Standard Approval Duration: As requested up to a maximum of 10 days before the date of surgery plus up to 7 days after surgery. For post-operative prophylaxis of DVT for patients who had hip or knee surgery, and cannot use warfarin. Standard Approval Duration: As requested up to a maximum of 30 days starting on the day of surgery. For the post-operative prophylaxis of venous thromboembolism following abdominal or pelvic surgery for cancer in patients who do not have a history of or risk factors for heparin-induced thrombocytopenia. Standard Approval Duration: Maximum of 30 days For extended treatment of symptomatic acute venous thromboembolism (VTE) in patients with cancer for whom warfarin treatment is not appropriate on a case-by-case basis. Standard Approval Duration: 6 months 28 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 28, record 7, corpus 2025-01-01; name match only, not an eligibility decision Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Dalteparin Brand(s): Fragmin DOSAGE FORM/ STRENGTH: Check e-formulary for funded strengths 1. For peri-operative bridging for patients who require long-term warfarin therapy and must temporarily discontinue it before and after surgery, and who are at moderate- to high-risk for an embolic event while off warfarin. Standard Approval Duration: As requested up to a maximum of 10 days before the date of surgery plus up to 7 days after the date of hospital discharge 2. For post-operative prophylaxis of DVT for patients who had hip or knee surgery and cannot use warfarin. Standard Approval Duration: As requested up to a maximum of 30 days starting on the day of surgery 3. For the post-operative prophylaxis of venous thromboembolism following abdominal or pelvic surgery for cancer in patients who do not have a history of or risk factors for heparin-induced thrombocytopenia. Standard Approval Duration: Maximum of 30 days. 4. For extended treatment of symptomatic acute venous thromboembolism (VTE) in patients with cancer, who cannot use warfarin. Standard Approval Duration: As requested up to 6 months 469 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 469, record 308, corpus 2025-01-01; name match only, not an eligibility decision

Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 15, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days | (ontario.ca, Updated September 15, 2026 ↗) For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated September 15, 2026 ↗)

Fragmin · DIN 02494582 Manufacturer: Pfizer Canada Inc.; listing date 2021-02-26 Health Canada: Marketed since 2020-06-08 · brand FRAGMIN · ATC B01AB04 DALTEPARIN · form Solution · route Intravenous, Subcutaneous · ingredients DALTEPARIN SODIUM 16500 UNIT/0.66ML · company Pfizer canada ulc · schedule Prescription

DIN 02494582: Fragmin Raw flags: sec12=Y, sec3=Y Item: 201200105; group id 253; item number 0456; lccId 00045; manufacturer id PFI Source form: Inj Pref Syr-0.66mL Pk; strength: 16500IU/0.66mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $39.9223; ministry $39.9223 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02494582 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98458

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02494582

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Reason for Use code 186 For acute treatment of deep venous thrombosis (DVT), for a maximum of three weeks; Coverage limit: LU Authorization Period: 1 year Reason for Use code 187 For DVT in pregnant or lactating females; Coverage limit: LU Authorization Period: 1 year Reason for Use code 188 For DVT in patients whom treatment with warfarin is not tolerated, or contraindicated; Coverage limit: LU Authorization Period: 1 year Reason for Use code 189 For DVT in patients who have failed treatment with warfarin. Coverage limit: LU Authorization Period: 1 year Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Dalteparin Brand(s): Fragmin DOSAGE FORM/ STRENGTH: Check formulary or e-formulary for funded products For peri-operative bridging for patients who require long-term warfarin therapy and must temporarily discontinue it before and after surgery, and who are at moderate- to high-risk for an embolic event while off warfarin. Standard Approval Duration: As requested up to a maximum of 10 days before the date of surgery plus up to 7 days after surgery. For post-operative prophylaxis of DVT for patients who had hip or knee surgery, and cannot use warfarin. Standard Approval Duration: As requested up to a maximum of 30 days starting on the day of surgery. For the post-operative prophylaxis of venous thromboembolism following abdominal or pelvic surgery for cancer in patients who do not have a history of or risk factors for heparin-induced thrombocytopenia. Standard Approval Duration: Maximum of 30 days For extended treatment of symptomatic acute venous thromboembolism (VTE) in patients with cancer for whom warfarin treatment is not appropriate on a case-by-case basis. Standard Approval Duration: 6 months 28 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 28, record 7, corpus 2025-01-01; name match only, not an eligibility decision Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Dalteparin Brand(s): Fragmin DOSAGE FORM/ STRENGTH: Check e-formulary for funded strengths 1. For peri-operative bridging for patients who require long-term warfarin therapy and must temporarily discontinue it before and after surgery, and who are at moderate- to high-risk for an embolic event while off warfarin. Standard Approval Duration: As requested up to a maximum of 10 days before the date of surgery plus up to 7 days after the date of hospital discharge 2. For post-operative prophylaxis of DVT for patients who had hip or knee surgery and cannot use warfarin. Standard Approval Duration: As requested up to a maximum of 30 days starting on the day of surgery 3. For the post-operative prophylaxis of venous thromboembolism following abdominal or pelvic surgery for cancer in patients who do not have a history of or risk factors for heparin-induced thrombocytopenia. Standard Approval Duration: Maximum of 30 days. 4. For extended treatment of symptomatic acute venous thromboembolism (VTE) in patients with cancer, who cannot use warfarin. Standard Approval Duration: As requested up to 6 months 469 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 469, record 308, corpus 2025-01-01; name match only, not an eligibility decision

Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 15, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days | (ontario.ca, Updated September 15, 2026 ↗) For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated September 15, 2026 ↗)

Fragmin · DIN 02352680 Manufacturer: Pfizer Canada Inc.; listing date 2011-03-15 Health Canada: Marketed since 2011-02-01 · brand FRAGMIN · ATC B01AB04 DALTEPARIN · form Solution · route Subcutaneous, Intravenous · ingredients DALTEPARIN SODIUM 18000 UNIT/0.72ML · company Pfizer canada ulc · schedule Prescription

DIN 02352680: Fragmin Raw flags: sec12=Y, sec3=Y Item: 201200067; group id 253; item number 0455; lccId 00045; manufacturer id PFI Source form: Inj Pref Syr; strength: 18000IU/0.72mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $43.5520; ministry $43.5520 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02352680 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83794

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02352680

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Reason for Use code 186 For acute treatment of deep venous thrombosis (DVT), for a maximum of three weeks; Coverage limit: LU Authorization Period: 1 year Reason for Use code 187 For DVT in pregnant or lactating females; Coverage limit: LU Authorization Period: 1 year Reason for Use code 188 For DVT in patients whom treatment with warfarin is not tolerated, or contraindicated; Coverage limit: LU Authorization Period: 1 year Reason for Use code 189 For DVT in patients who have failed treatment with warfarin. Coverage limit: LU Authorization Period: 1 year Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Dalteparin Brand(s): Fragmin DOSAGE FORM/ STRENGTH: Check formulary or e-formulary for funded products For peri-operative bridging for patients who require long-term warfarin therapy and must temporarily discontinue it before and after surgery, and who are at moderate- to high-risk for an embolic event while off warfarin. Standard Approval Duration: As requested up to a maximum of 10 days before the date of surgery plus up to 7 days after surgery. For post-operative prophylaxis of DVT for patients who had hip or knee surgery, and cannot use warfarin. Standard Approval Duration: As requested up to a maximum of 30 days starting on the day of surgery. For the post-operative prophylaxis of venous thromboembolism following abdominal or pelvic surgery for cancer in patients who do not have a history of or risk factors for heparin-induced thrombocytopenia. Standard Approval Duration: Maximum of 30 days For extended treatment of symptomatic acute venous thromboembolism (VTE) in patients with cancer for whom warfarin treatment is not appropriate on a case-by-case basis. Standard Approval Duration: 6 months 28 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 28, record 7, corpus 2025-01-01; name match only, not an eligibility decision Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Dalteparin Brand(s): Fragmin DOSAGE FORM/ STRENGTH: Check e-formulary for funded strengths 1. For peri-operative bridging for patients who require long-term warfarin therapy and must temporarily discontinue it before and after surgery, and who are at moderate- to high-risk for an embolic event while off warfarin. Standard Approval Duration: As requested up to a maximum of 10 days before the date of surgery plus up to 7 days after the date of hospital discharge 2. For post-operative prophylaxis of DVT for patients who had hip or knee surgery and cannot use warfarin. Standard Approval Duration: As requested up to a maximum of 30 days starting on the day of surgery 3. For the post-operative prophylaxis of venous thromboembolism following abdominal or pelvic surgery for cancer in patients who do not have a history of or risk factors for heparin-induced thrombocytopenia. Standard Approval Duration: Maximum of 30 days. 4. For extended treatment of symptomatic acute venous thromboembolism (VTE) in patients with cancer, who cannot use warfarin. Standard Approval Duration: As requested up to 6 months 469 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 469, record 308, corpus 2025-01-01; name match only, not an eligibility decision

Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 15, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days | (ontario.ca, Updated September 15, 2026 ↗) For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated September 15, 2026 ↗)

Fragmin · DIN 02231171 Manufacturer: Pfizer Canada Inc.; listing date 1998-12-31 Health Canada: Marketed since 2005-05-20 · brand FRAGMIN · ATC B01AB04 DALTEPARIN · form Solution · route Intravenous, Subcutaneous · ingredients DALTEPARIN SODIUM 25000 UNIT/ML · company Pfizer canada ulc · schedule Prescription

DIN 02231171: Fragmin Raw flags: sec12=Y, sec3=Y Item: 201200043; group id 253; item number 0457; lccId 00045; manufacturer id PFI Source form: Multidose 3.8mL Pk; strength: 25000IU/mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $181.4839; ministry $181.4839 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02231171 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=50478

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02231171

Shortage record checked 2026-09-13T08:10:21.292534+00:00